Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: Evidence for coverage decisions in Thailand

Value in Health

Volumn 10, Issue 1, 2007, Pages 61-72

  Teerawattananon, Yot ^a,b   Mugford, Miranda ^b   Tangcharoensathien, Viroj ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Dialysis; Economic evaluation; Renal failure; Thailand; Value of information

Indexed keywords

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PALLIATIVE THERAPY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; THAILAND;

EID: 33846547693     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2006.00145.x     Document Type: Article

References (51)

1. Stanton J. The cost of living: kidney dialysis, rationing and health economics in Britain, 1965-1996. Soc Sci Med 1999;49:1169-82.
2. Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002;22:417-30.
3. Garner T, Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care 1987;25:25-34.
4. Croxson BE, Ashton T. A cost effectiveness analysis of the treatment of end stage renal failure. N Z Med J 1990;103:171-4.
5. Sesso R, Eisenberg JM, Stabile C, et al. Cost-effectiveness analysis of the treatment of end-stage renal disease in Brazil. Int J Technol Assess Health Care 1990;6:107-14.
6. Karlberg I, Nyberg G. Cost-effectiveness studies of renal transplantation. Int J Technol Assess Health Care 1995;11:611-22.
7. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996;50:235-42.
8. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998;44:215-32.
9. Weydevelt C-V, Bacquaert-Dufour K, Benevent D, et al. A cost-effectiveness analysis of continuous ambulatory peritoneal dialysis vs. self-care in-center hemodialysis in France. Dial Transplant 1999;28:70-4.
10. Mohr PE, Neumann PJ, Franco SJ, et al. The case for daily dialysis: its impact on costs and quality of life. Am J Kidney Dis 2001;37:777-89.
11. Sennfalt K, Magnusson M, Carlsson P. Comparison of hemodialysis and peritoneal dialysis - A cost-utility analysis. Perit Dial Int 2002;22:39-47.
12. Mowatt G, Vale L, Perez J, et al. Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. Health Technol Assess 2003;7:1-174.
13. Gonzalez-Perez JG, Vale L, Stearns SC, et al. Hemodialysis for end-stage renal disease: a cost-effectiveness analysis of treatment-options. Int J Technol Assess Health Care 2005;21:32-9.
14. Hooi LS, Lim TO, Goh A, et al. Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia. Nephrology (Carlton) 2005;10:25-32.
15. Kaitelidou D, Ziroyanis PN, Maniadakis N, et al. Economic evaluation of hemodialysis: implications for technology assessment in Greece. Int J Technol Assess Health Care 2005;21:40-6.
16. Jitanan A. Thailand Renal Replacement Therapy (TRT) registry: a report of 1997-2001. J Nephrol Soc Thai 2002;8:167-79.
17. Krilithichai U, Supaporn T, Lakyanon S, et al. Thailand Registry of Renal Replacement Therapy: a report of 1997-2003. J Nephrology Soc Thailand 2003;9:210-25.
18. Towse A, Mills A, Tangcharoensathien V. Learning from Thailand's health reforms. BMJ 2004;328:103-5.
19. Tangcharoensathien V, Teerawattananon Y, Kasamesup V, Mukem S. The policy analysis of renal replacement therapy for end stage renal disease patients in basic care package of universal health insurance in Thailand. Thai Med Council Bull 2001;30:215-26.
20. Teerawattananon Y, Tangcharoensathien V. Designing a reproductive health services package in the universal health insurance scheme in Thailand: match and mismatch of need, demand and supply. Health Policy Plan 2004;19(Suppl. 1):Si31-i9.
21. Tangcharoensathien V, Kasemsup V, Teerawattananon Y, et al. Universal Access to Renal Replacement Therapy in Thailand: a Policy Analysis. Nonthaburi: International Health Policy Program & Nephrology Society of Thailand, 2005.
22. Teerawattananon Y. Guideline for Conducting Economic Evaluation in the ACCEPT Project. Nonthaburi: Assessing Cost and Cost-Effectiveness for Priorities in Thailand - ACCEPT Project, 2004.
23. Teerawattananon Y, Mugford M. Is it worth offering a routine laparoscopic cholecystectomy in developing countries? A Thailand case study. Cost Eff Resour Alloc 2005;3:10.
24. Korevaar JC, Feith GW, Dekker FW, et al. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int 2003;64:2222-8.
25. MacLeod A, Wallace S, Grant A, et al. Effectiveness and efficacy of methods of dialysis therapy for end-stage renal disease: systematic reviews. In: Health Technology Assessment (Vol. 2, Series Effectiveness and Efficacy of Methods of Dialysis Therapy for End-Stage Renal Disease: Systematic Reviews). Southampton: York Publishing Services, 1998.
26. Van Biesen W, Vanholder R, Debacquer D, et al. Comparison of survival on CAPD and haemodialysis: statistical pitfalls. Nephrol Dial Transplant 2000;15:307-11.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
28. Bradburn MJ, Clark TG, Love SB, et al. Survival analysis part III: multivariate data analysis - choosing a model and assessing its adequacy and fit. Br J Cancer 2003;89:605-11.
29. Briggs A, Claxton K, Sculpher M. Decision Modelling Methods for Health Economic Evaluation. Oxford: Oxford University Press, 2006.
30. Bundhamcharoen K, Teerawattananon Y, Theo V, et al. Burden of disease and injuries in Thailand: priority setting for policy. Bangkok, 2002. Available from: http://203.157.19.191/BURDEN.pdf [Accessed July 17, 2004].
31. Clark TG, Bradburn MJ, Love SB, et al. Survival analysis part I: basic concept and first analyses. Br J Cancer 2003;89:232-8.
32. Wongsiripisaan A, Dandecha P, Sangthawaan P, et al. Peritoneal dialysis using double bags and Y-set: experience from Songkhlanakarin Hospital. J Kidney Found Thai 2003;9:241-50.
33. Sriwajana P. Comparative survival of patients with chronic renal failure on hemodialysis and continuous ambulatory peritoneal dialysis. Pramongkutklao Hospital [Master's thesis]. Salaya: Mahidol, 1997.
34. Maharatanavirosn W. Quality of life of patients with end stage renal disease on hemodialysis and continuous ambulatory peritoneal dialysis [Master's Thesis]. Salaya: Mahidol, 1999.
35. Pukpobsuk N. Determination of quality of life in end-stagerenal disease patients on hemodialysis and continuous ambulatory peritoneal dialysis [Master's thesis]. Salaya: Mahidol, 2001.
36. Kusoom V, Lapjaroengwong N. Quality of life of patients with end-stage renal disease and receiving renal replacement therapy. Vajira Med J 2004;48:107-15.
37. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997;16:33-64.
38. Tisayathikom K, Patcharanalumol W, Mukem S, et al. Cost and Efficiency of Public and Private Hemodialysis Centers in 2001. Nonthaburi: International Health Policy Program, 2003.
39. Homvijitkul J. Health expenditure of patients with end stage renal disease on hemodialysis and continuous ambulatory peritoneal dialysis [Master's thesis]. Salaya: Mahidol, 1999.
40. International Monetary Fund. The World Economic Outlook Database. Washington, DC: IMF Publication Services, 2005.
41. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500.
42. Daniels MJ, Zhao YD. Modelling the random effects covariance matrix in longitudinal data. Stat Med 2003;22:1631-47.
43. Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005;14:339-47.
44. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-87.
45. Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making 1998;18:95-109.
46. Tappenden P, Chilcott JB, Eggington S, et al. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. Health Technol Assess 2004;8:iii.
47. Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modeling. Med Decis Making 2004;24:207-27.
48. The Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization, 2002.
49. Teerawattananon Y, Vos T, Tangcharoensathien V, et al. Cost-effectiveness of models for prevention of vertical HIV transmission - voluntary counseling and testing and choices of drug regimen. Cost Eff Resour Alloc 2005;3:7.
50. Manns B, Meltzer D, Taub K, et al. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care. Health Econ 2003;12:949-58.
51. Hooi LS, Lim TO, Goh A, et al. Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia. Nephrology 2005;10:25-32.